Amedisys Inc

Amedisys — Q4 2020 Earnings Presentation

22 slides from Amedisys's earnings presentation, Feb 24, 2021

  1. Slide 1: Fourth Quarter and Year End 2020 Earnings Call Supplemental Slides

    Amedisys Fourth Quarter and Year End 2020 Earnings Call Supplemental Slides February 25, 2021 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cau

  3. Slide 3: Q4 and Year End 2020 Results

    Q4 and Year End 2020 Results amedisys

  4. Slide 4: A Look Back: FY 2020 Accomplishments

    A Look Back FY 2020 Accomplishments Employer of Choice Ended the year with overall voluntary turnover of 18.3% Focused our turnover efforts to drive down early exits, enabling us to focus on hiring and retaining the right talent. We reduced our early exit rate by 6% over 2019, ending 2020 at 11.9% C

  5. Slide 5: Our Key Areas of Focus

    Our Key Areas of Focus Strategic areas of focus and progress made during Q4’20 Home Health*: Total same store admissions +6%, Total same store volume +5% Hospice: Admissions +15% Personal Care: Billable hours / quarter -17% driven by impact of COVID-19. Personal Care Network drove ~$3.5M revenue to

  6. Slide 6: Key focus areas for 2021 and beyond

    Expanding and executing on 2020 initiatives extends to our key focus areas for 2021 and beyond. Preparing for outsized growth, continued M&A industry disruption / consolidation, integration of new assets and close-to-core innovations will be our areas of focus Optimize current PCL Business, Operatio

  7. Slide 7: Highlights and Summary Financial Results (Adjusted): 4Q 2020

    Highlights and Summary Financial Results (Adjusted): 4Q 2020(1) Home Health total same store volume +5%, total same store admissions +6%; Hospice same store admissions +15% Amedisys Consolidated Revenue Growth: +10% EBITDA: $78M (+50%) EBITDA Margin: 14% (+380 bps) EPS: $1.49 (+59%) 4Q’20 Net debt:

  8. Slide 8: Our Revenue Sources: 4Q'20

    Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per Day Reimbursem

  9. Slide 9: Home Health and Hospice Segment (Adjusted) – 4Q 2020

    Home Health and Hospice Segment (Adjusted) – 4Q 2020(1) Revenue per Episode up 1.9% (sequestration suspension benefit $5M) Y/Y CPV up $6.43 (+6.8%, primarily due to raises effective 8/1, an increase in contractor utilization and new hire pay, and lower visit volumes) Visits per Episode decreased 2.8

  10. Slide 10: General & Administrative Expenses – Adjusted

    General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 90 basis points ($21 million) Year over year G&A increase due to our acquisitions (~$11M = Hospice segment ~$9M; Corporate segment ~$2M), raises, incentive accruals, higher health

  11. Slide 11: Cost per Visit Components

    Components 4Q19 3Q’20 4Q’20 YoY Variance Detail Initiatives Salaries $64.18 $64.81 $66.09 $1.91 YoY increase due to planned wage increases, shift in visit mix and fixed costs (training, PTO, etc.) on lower visits, partially offset by optimization of discipline mix. Sequential increase due to higher

  12. Slide 12: Driving Top Line Growth

    Driving Top Line Growth Home Health growth remains strong. Hospice admissions very strong but ADC lagging due to shorter lengths of stay as a result of higher death rate. Personal Care billable hours impacted by COVID-19 Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter

  13. Slide 13: Hospice ADC Experience

    Hospice ADC Experience Increased deaths and patients delaying care driven by COVID-19 concerns impacted ADC growth (top left). Though average discharge length of stay increased year over year, median discharge length of stay was significantly down while both percentage of discharges 14 days or less

  14. Slide 14: Industry Leading Quality Scores

    Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 Release Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric OCT 19 Release JAN 20

  15. Slide 15: Hospice Quality

    Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022

  16. Slide 16: Debt and Liquidity Metrics

    Debt and Liquidity Metrics ~Net leverage ~0.7x Net debt defined as total debt outstanding ($217.7M) less cash ($21.8M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($273.5M). Liquidity defined as the sum of cash balance and available revolving line of cr

  17. Slide 17: Cash Flow Statement Highlights

    Cash Flow Statement Highlights (1) Q2, Q3 and Q4 include benefit of payroll tax deferral (COVID-19 relief) of approximately $20M, $18M and $17M respectively. Q4 also includes ~$15M in additional tax payments related to treatment of CARES Act funds. Total payroll tax deferral of ~$55.4M due back as ~

  18. Slide 18: Income Statement Adjustments

    Income Statement Adjustments (1) The financial results for the three-month periods ended December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020 and December 31, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP

  19. Slide 19: 2021 Guidance

    2021 Guidance 6 amedisys

  20. Slide 20: Amedisys 2021 Preliminary Guidance

    Amedisys 2021 Preliminary Guidance Note: Adjusted numbers are ex-CARES Act funds *EPS: Inclusive of $0.72 income tax benefit related to executive stock option exercise Revenue, EBITDA and EPS guidance ranges for FY 2021 2020 Actual Performance 2021 Guidance Revenue Adjusted EBITDA $274M $2,072M Adju

  21. Slide 21: 2021 Guidance Considerations

    2021 Guidance Considerations Amedisys Consolidated Tax rate ~26% Cash tax rate ~15% Diluted share count ~33.4 million shares Capital Expenditures ~$6-$8 million Salary increase ~2% - 3% Benefits increase ~14% (9% growth / headcount, 5% pricing / claims costs) Overall ~$10 million investment in busin

  22. Slide 22: 2021 Hospice ADC Projection

    2021 Hospice ADC Projection Hospice ADC was building entering Q4’20. Revised projections have ADC returning to pre-Q4 ADC forecast exiting 2021 ADC impact developed in late Q4 AseraCare Acquisition

Amedisys — Q4 2020 Earnings Presentation on 6ix